North America remains a dominant regional market for neuroendocrine carcinoma treatment owing to increasing cancer awareness, strong research and development capabilities, and widespread access to advanced healthcare services. The region benefits from a well-established regulatory framework, growing adoption of personalized medicine, and continuous advancements in cancer diagnostics and...